Company: Intra-Cellular Therapies
Tags: pipeline, territory
The MDD approval for Caplyta has been a complete game changer in my territory. I went from calling on psychiatrists only to now having a real story for primary care. Volume has nearly doubled in six months. The differentiator of no weight gain and no sexual dysfunction resonates immediately with primary care docs who are sick of patients complaining about SSRIs. Pull-through is manageable, managed care access is better than I expected. Intra-Cellular is a smaller company so the support isn't always perfect but the reps I've met are hungry and the product sells. Bullish on where this goes in 20
35 upvotes · 0 comments